Correlation Between Crinetics Pharmaceuticals and CytomX Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Crinetics Pharmaceuticals and CytomX Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crinetics Pharmaceuticals and CytomX Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crinetics Pharmaceuticals and CytomX Therapeutics, you can compare the effects of market volatilities on Crinetics Pharmaceuticals and CytomX Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crinetics Pharmaceuticals with a short position of CytomX Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crinetics Pharmaceuticals and CytomX Therapeutics.

Diversification Opportunities for Crinetics Pharmaceuticals and CytomX Therapeutics

-0.64
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Crinetics and CytomX is -0.64. Overlapping area represents the amount of risk that can be diversified away by holding Crinetics Pharmaceuticals and CytomX Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CytomX Therapeutics and Crinetics Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crinetics Pharmaceuticals are associated (or correlated) with CytomX Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CytomX Therapeutics has no effect on the direction of Crinetics Pharmaceuticals i.e., Crinetics Pharmaceuticals and CytomX Therapeutics go up and down completely randomly.

Pair Corralation between Crinetics Pharmaceuticals and CytomX Therapeutics

Given the investment horizon of 90 days Crinetics Pharmaceuticals is expected to generate 0.65 times more return on investment than CytomX Therapeutics. However, Crinetics Pharmaceuticals is 1.54 times less risky than CytomX Therapeutics. It trades about 0.11 of its potential returns per unit of risk. CytomX Therapeutics is currently generating about -0.07 per unit of risk. If you would invest  5,162  in Crinetics Pharmaceuticals on August 16, 2024 and sell it today you would earn a total of  730.00  from holding Crinetics Pharmaceuticals or generate 14.14% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Crinetics Pharmaceuticals  vs.  CytomX Therapeutics

 Performance 
       Timeline  
Crinetics Pharmaceuticals 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Crinetics Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Crinetics Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.
CytomX Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days CytomX Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's primary indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Crinetics Pharmaceuticals and CytomX Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Crinetics Pharmaceuticals and CytomX Therapeutics

The main advantage of trading using opposite Crinetics Pharmaceuticals and CytomX Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crinetics Pharmaceuticals position performs unexpectedly, CytomX Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will offset losses from the drop in CytomX Therapeutics' long position.
The idea behind Crinetics Pharmaceuticals and CytomX Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Other Complementary Tools

Stocks Directory
Find actively traded stocks across global markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges